The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors.
about
Discovery of 4-Amino-1-(7 H -pyrrolo[2,3- d ]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt)Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signalingRecent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agentsPleckstrin homology domain of Akt kinase: a proof of principle for highly specific and effective non-enzymatic anti-cancer targetSelective blockade of protein kinase B protects the rat and human myocardium against ischaemic injuryA novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.A chemical epitope-targeting strategy for protein capture agents: the serine 474 epitope of the kinase Akt2.Inositol pentakisphosphate isomers bind PH domains with varying specificity and inhibit phosphoinositide interactionsAkt phosphorylation and regulation of transketolase is a nodal point for amino acid control of purine synthesisTherapeutic targeting of integrin αvβ6 in breast cancer.Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival.A phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study.Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.Akt determines cell fate through inhibition of the PERK-eIF2α phosphorylation pathwayProapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia.From oncogene to network addiction: the new frontier of cancer genomics and therapeutics.Negative feedback that improves information transmission in yeast signallingIdentification and quantification of AKT isoforms and phosphoforms in breast cancer using a novel nanofluidic immunoassay.Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy.Recent development of anticancer therapeutics targeting Akt.A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.Human kinome drug discovery and the emerging importance of atypical allosteric inhibitors.Targeting the unactivated conformations of protein kinases for small molecule drug discovery.PDK1 inhibitorsMK-2206 causes growth suppression and reduces neuroendocrine tumor marker production in medullary thyroid cancer through Akt inhibition.PDK1 disruptors and modulators: a patent review.BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells.Synthesis and antitumor activity of inositol phosphotriester analogues.Design, synthesis, and structure-activity relationships of 3-ethynyl-1H-indazoles as inhibitors of the phosphatidylinositol 3-kinase signaling pathwayInhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation status.BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma.AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8 T cells for adoptive immunotherapy
P2860
Q27659777-A62244A6-CD58-494A-AB40-9A495A2C8B6CQ27851446-EB239F94-6ACA-4F05-B2F3-B5D0E9DD0419Q28067417-8758CA8D-C321-49D2-9378-8188959D5660Q28485326-B1545682-831E-4605-A729-6086D5B23186Q28567327-8B47DAB3-01CB-4430-8957-9FB2EEE2EF20Q33620076-0DB52750-F72B-408D-B3E4-A65DC96AB61AQ33760966-EF437A40-3717-4F31-B9FC-CFA028F80006Q33817574-3DA0E87A-9FF6-4DC3-9798-342977169DB1Q33923074-5BB8095C-A0A0-440A-8D03-3929486330F6Q34120685-BBA5BE3A-7427-4C2A-8D2D-02B92CC111B4Q34127007-7C00BBC6-E644-47E3-B5C9-AE95AD61991DQ35085742-8228472C-B47A-4862-8FC4-5A05E8CED0E1Q35684517-31C26B76-CC42-43E7-B7C0-A207B6B07B77Q36436853-A9CA3E61-61BE-4DB7-A039-EE292A099A16Q37119471-0FF2E831-CDE4-4C67-A129-86B9FFD67D3BQ37138122-EF466DCF-9630-455C-84BB-38FC18457E7FQ37236447-D3A8B1F3-DF48-4AC6-8A04-4BAEFBB95633Q37277701-9FE7CDBB-7034-4DF5-874F-5DC4C55C5C4DQ37289400-5F0A9EF7-A64D-4763-951E-2F8C88945F90Q37367106-98437270-117F-4383-843D-48AE4F61AA7DQ37812658-EBB1E13E-05AD-45AA-AE0D-19278F8ABA96Q37921836-E609C9DE-B713-42BE-8EAB-8D3B59ABDA16Q38028535-8B4BBD6B-B6A8-4865-80AB-5E9F7E76C07DQ38090668-B745691F-D42E-40B5-92AE-B609E4627CFEQ38162915-BAF8AECD-4DB0-4F91-874E-BA0737AA9A95Q38287178-3EEBA19F-E2F9-45D7-B98F-2CF1B364D33AQ38356458-19C71923-92FB-4AFE-AA68-84EE9F855629Q38739375-C1AFAD8E-52F1-45AF-A2B1-09058C6B6E02Q38962245-7C3258A9-2741-4BAA-A270-64653C0AA68AQ39370488-5039C838-D0D8-42A1-B0A2-361D7333FBCCQ39634158-8244F6BA-C59C-434C-BC6A-24957BE9AF3FQ39680470-267F411E-B959-42DD-9F92-4DCC5843633FQ39890111-EA5AC1C4-49D7-4442-91A5-468A61E64B08Q57135104-765284B0-463B-45E4-AFB9-C72F0B982C26
P2860
The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The PI3K/Akt pathway: recent p ...... osteric Akt kinase inhibitors.
@en
The PI3K/Akt pathway: recent p ...... osteric Akt kinase inhibitors.
@nl
type
label
The PI3K/Akt pathway: recent p ...... osteric Akt kinase inhibitors.
@en
The PI3K/Akt pathway: recent p ...... osteric Akt kinase inhibitors.
@nl
prefLabel
The PI3K/Akt pathway: recent p ...... osteric Akt kinase inhibitors.
@en
The PI3K/Akt pathway: recent p ...... osteric Akt kinase inhibitors.
@nl
P2093
P1476
The PI3K/Akt pathway: recent p ...... osteric Akt kinase inhibitors.
@en
P2093
Mark E Layton
Mark T Bilodeau
Stanley F Barnett
P356
10.2174/156800908783497096
P577
2008-02-01T00:00:00Z